Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On

Designing T-Cell Engagers: Trade-Offs Between Activity and Safety

June 5, 2026

[Protein & Cell] Scientists analyze principal T cell engager design strategies, examining their respective strengths, limitations, and interdependencies.

Exploring CAR Cell Therapies Beyond CAR-T for Myeloid Malignancies

June 5, 2026

[Journal of Biomedical Science] The authors highlight the challenges of applying conventional CAR-T cells to myeloid malignancies, examine emerging alternative CAR-cell platforms, and discuss how their unique biology and engineering strategies may provide safer, more effective, and more accessible therapeutic options for patients with these difficult-to-treat cancers.

Coexpression of IL15 Promotes Effector Differentiation and Sustained Proliferative Capacity in ALPPL2-Specific Human CAR T Cells

June 5, 2026

[Cancer Immunology Research] Scientists reported a CAR construct (ABBz) assembled from human sequences including a single-chain variable fragment specific to alkaline phosphatase, placental-like 2 (ALPPL2). ABBz CAR T cells had robust antitumor activity, which was further enhanced through IL15 coexpression, resulting in NK-like effector differentiation with increased cytotoxicity.

Hallmarks and Correlates of Effective Adoptive Cell Immunotherapy for Cancer

June 3, 2026

[Nature Reviews Immunology] Scientists highlight emerging correlates of response to adoptive cell transfer and novel strategies that integrate tumor immunology, cancer genomics, computational biology, and T cell engineering for the development of next-generation cellular immunotherapies.

CellChorus and Stanford Medicine Awarded NCI Grant to Develop AI-Driven Functional Assay Predicting CAR-T Response in Lymphoma Patients

May 25, 2026

[CellChorus, Inc.] CellChorus, Inc. announced that the National Cancer Institute has awarded CellChorus® and Stanford Medicine a Phase I Small Business Innovation Research grant to profile cells from relapsed/refractory large B cell lymphoma patients after treatment with CAR-T cell therapy to develop a functional signature of response to therapy.

The In Vivo Revolution in CAR-T Therapy Medicinal Products: Challenges and Regulatory Prospects

May 25, 2026

[Signal Transduction and Targeted Therapy] The emergence of in vivo CAR-T therapy medicinal products using viral vector or lipid nanoparticle platforms has provided a promising new direction by simplifying manufacturing, enhancing scalability, and lowering costs, though it may introduce elevated risks such as off-target effects and immunogenicity.

Armored Chimeric Antigen Receptor T Cell Therapy Targets Antigen-Heterogeneous Glioma

May 25, 2026

[Cancer Research] Through head-to-head in vivo comparisons of potentially synergistic armor combinations, researchers demonstrated that T cells expressing a CAR plus IL-12 and the decoy-resistant form of IL-18 show strong efficacy against antigen-heterogeneous glioma in immunocompetent mice.

Resetting Autoimmune Disease with CAR Cell Therapies

May 25, 2026

[Nature Medicine] CAR-expressing cells—initially developed and successfully used to treat certain cancers—are increasingly being developed to selectively deplete B cells and ‘reset’ the immune system in autoimmune diseases (AIDs).

Tumor Irradiation Promotes Antigen Dressing of Dendritic Cells to Enhance CAR T Cell Persistence and Efficacy in Lung Metastases

May 25, 2026

[Nature Cancer] Using syngeneic models of extensive metastatic lung adenocarcinoma and melanoma, investigators showed that 8 Gy of tumor irradiation significantly enhanced CAR T cell persistence in a manner critically dependent on dendritic cells.

Challenges and Advances in CAR-T Cell Therapy for B-ALL

May 25, 2026

[Biomarker Research] The authors discuss the limitations of CAR-T and strategies to overcome them, specifically in the context of B cell acute lymphoblastic leukemia, including the use of allogeneic CAR-T, dual-targeted CAR-T, and combination strategies with novel technologies and agents.

Bioengineering CAR-T Cells to Function in Hostile Tumor Microenvironments

May 25, 2026

[Trends in Biotechnology] This review synthesizes recent advances in CAR-T cell bioengineering aimed at overcoming physical barriers, immunosuppressive signaling, metabolic stress, and cellular exhaustion that characterize solid tumors, which are a leading cause of cancer-related mortality worldwide.

IL-15 and IL-21 Synergy Improves Anti-Tumor Efficacy of iPSC-Derived Cytotoxic T Cells in Solid Tumors

May 25, 2026

[Molecular Therapy] Researchers engineered iPSC-derived cytotoxic T cells transduced with a CAR and identified an optimal cytokine armoring strategy. Co-expression of interleukin (IL)-15 and IL-21 synergistically enhanceds STAT1 phosphorylation, leading to increased transcriptional activation of the chemokine receptor CXCR3.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.